Thrombotic microangiopathic glomerulopathy in human decay accelerating factor-transgenic swine-to-baboon kidney xenografts.
Models of pig-to-baboon xenografting were examined to identify the mechanisms and pathologic characteristics of acute humoral xenograft rejection (AHXR). Thymus and kidney (composite thymokidney) from human decay accelerating factor-transgenic swine were transplanted into baboons (n = 16) that were treated with an immunosuppressive regimen that included extracorporeal immunoadsorption of anti-alphaGal antibody and inhibition of complement activation. Morphologic and immunohistochemical studies were performed on protocol biopsies and graftectomy samples. All renal xenografts avoided hyperacute rejection. However, graft rejection coincided with the increase of anti-alphaGal antibody in the recipient's circulation. The 16 xenografts studied were divided into two groups dependent on the rapid return (group 1) or gradual return (group 2) of anti-alphaGal antibody after immunoadsorption. In group 1 (n = 6), grafts were rejected to day 27 with development of typical AHXR, characterized by marked interstitial hemorrhage and thrombotic microangiopathy in the renal vasculature. In group 2 (n = 10), grafts also developed thrombotic microangiopathy affecting mainly the glomeruli by day 30 but also showed minimal evidence of interstitial injury and hemorrhage. In the injured glomeruli, IgM and C4d deposition, subsequent endothelial cell death and activation with upregulation of von Willebrand factor and tissue factor, and a decrease of CD39 expression developed with the formation of fibrin-platelet multiple microthrombi. In this model, the kidney xenografts, from human decay accelerating factor-transgenic swine, in baboons undergo AHXR. In slowly evolving AHXR, graft loss is associated with the development of thrombotic microangiopathic glomerulopathy. Also, anti-alphaGal IgM deposition and subsequent complement activation play an important role in the mechanism of glomerular endothelial injury and activation and the formation of multiple microthrombi.
Shimizu
Akira
A
Transplantation Biology Research Center, Massachusetts General Hospital/Harvard Medical School, Boston, MA 02114, USA.
Yamada
Kazuhiko
K
Yamamoto
Shin
S
Lavelle
John M
JM
Barth
Rolf N
RN
Robson
Simon C
SC
Sachs
David H
DH
Colvin
Robert B
RB
D000208:Acute Disease; D000818:Animals; D030801:Animals, Genetically Modified; D018958:CD55 Antigens / Q000235:genetics* / Q000502:physiology; D005260:Female; D006084:Graft Rejection / Q000209:etiology / Q000276:immunology / Q000473:pathology; D006085:Graft Survival; D006801:Humans; D007674:Kidney Diseases / Q000209:etiology* / Q000276:immunology / Q000473:pathology; D007678:Kidney Glomerulus / Q000098:blood supply / Q000276:immunology / Q000473:pathology; D016030:Kidney Transplantation / Q000009:adverse effects* / Q000276:immunology; D008297:Male; D010215:Papio; D034421:Sus scrofa; D013927:Thrombosis / Q000209:etiology / Q000276:immunology / Q000473:pathology; D013950:Thymus Gland / Q000637:transplantation; D013997:Time Factors; D014183:Transplantation, Heterologous; D014652:Vascular Diseases / Q000209:etiology / Q000276:immunology / Q000473:pathology
D018958:CD55 Antigens